ARCUTIS BIOTHERAPEUTICS INC (ARQT) Stock Price & Overview
NASDAQ:ARQT • US03969K1088
Current stock price
The current stock price of ARQT is 23.63 USD. Today ARQT is down by -1.95%. In the past month the price decreased by -1.42%. In the past year, price increased by 60.42%.
ARQT Key Statistics
- Market Cap
- 2.931B
- P/E
- N/A
- Fwd P/E
- 73.82
- EPS (TTM)
- -0.14
- Dividend Yield
- N/A
ARQT Stock Performance
ARQT Stock Chart
ARQT Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ARQT. When comparing the yearly performance of all stocks, ARQT is one of the better performing stocks in the market, outperforming 76.07% of all stocks.
ARQT Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ARQT. The financial health of ARQT is average, but there are quite some concerns on its profitability.
ARQT Earnings
On February 25, 2026 ARQT reported an EPS of 0.13 and a revenue of 129.50M. The company beat EPS expectations (12.39% surprise) and beat revenue expectations (12.3% surprise).
ARQT Forecast & Estimates
14 analysts have analysed ARQT and the average price target is 35.7 USD. This implies a price increase of 51.08% is expected in the next year compared to the current price of 23.63.
For the next year, analysts expect an EPS growth of 328.65% and a revenue growth 37.71% for ARQT
ARQT Groups
Sector & Classification
ARQT Financial Highlights
Over the last trailing twelve months ARQT reported a non-GAAP Earnings per Share(EPS) of -0.14. The EPS increased by 87.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3.73% | ||
| ROE | -8.52% | ||
| Debt/Equity | 0.57 |
ARQT Ownership
ARQT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 174.171B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| MRNA | MODERNA INC | N/A | 19.759B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ARQT
Company Profile
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. The company is headquartered in Westlake Village, California and currently employs 354 full-time employees. The company went IPO on 2020-01-31. The firm is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.
Company Info
IPO: 2020-01-31
ARCUTIS BIOTHERAPEUTICS INC
3027 Townsgate Road, Suite 300
Westlake Village CALIFORNIA 91361 US
CEO: Todd Franklin Watanabe
Employees: 354
Phone: 18054185006
ARCUTIS BIOTHERAPEUTICS INC / ARQT FAQ
What does ARCUTIS BIOTHERAPEUTICS INC do?
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. The company is headquartered in Westlake Village, California and currently employs 354 full-time employees. The company went IPO on 2020-01-31. The firm is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.
What is the current price of ARQT stock?
The current stock price of ARQT is 23.63 USD. The price decreased by -1.95% in the last trading session.
Does ARCUTIS BIOTHERAPEUTICS INC pay dividends?
ARQT does not pay a dividend.
What is the ChartMill rating of ARCUTIS BIOTHERAPEUTICS INC stock?
ARQT has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the growth outlook for ARCUTIS BIOTHERAPEUTICS INC?
The Revenue of ARCUTIS BIOTHERAPEUTICS INC (ARQT) is expected to grow by 37.71% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the short interest for ARQT stock?
The outstanding short interest for ARCUTIS BIOTHERAPEUTICS INC (ARQT) is 14.08% of its float.